Document is current

Article History

Received: 25 March 2025

Accepted: 27 October 2025

First Online: 29 December 2025

Declarations

:

: We did not consider the patient feedback workshops to be research. These were designed to give patient and staff an opportunity to feedback about the current service. There were no fixed protocols or criteria. As such (and in line with the NHS research services guidance, which can be found at ), we did not need to seek ethics approval.

: Not applicable.

: PCT: Grants/research support from Alfasigma and payments made to the University of Oxford; consulting fees from AlfaSigma, AbbVie, ACELYRIN, INC., Biogen, Fresenius, Gilead Sciences, Inc., Roche; Takeda; Eli Lilly; Nordic Pharma; Pfizer; and UCB; safety monitoring board participation for Immunovant, Moonlake, and Sanofi. LS: Funding support for education, advisory board participation and/or received research funding from AbbVie, Almirall, Amgen, Aspire Pharma, Biogen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celgene, Celltrion, Fresenius Kabi, Galderma, Janssen, Leo, Lilly, Medac, Moonlake, Novartis, Pfizer, Sanofi, Takeda, UCB. CB: Research grant support from Amgen and Beiersdorf, consultancy for Abbvie and Beiersdorf. Honoraria received from Abbvie, Almirall, Galapagos, Novartis, Pfizer and UCB. LL: Funding support for education from Takeda. KB: Paid speaker for AbbVie, Jansen and Novartis. MS and LVR are employees of AbbVie and may hold AbbVie stock.